Impact of Breathing Exercises and Meditation on Improving Quality of Life in Glaucoma Patients

Sponsor
Lawson Health Research Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05960513
Collaborator
(none)
50
1
2
12
4.2

Study Details

Study Description

Brief Summary

Glaucoma is a chronic disease that causes loss of vision and potentially blindness as a result of optic nerve damage, often due to increased intraocular pressure. Glaucoma is currently the leading cause of irreversible blindness worldwide.1 In 2020, 4.1 million and 3.6 million adults over the age of 50 suffered from mild to severe glaucoma-induced visual impairment and blindness, respectively.1 However, these figures are likely underestimated since glaucoma can remain asymptomatic until later stages in disease progression.2 The relaxation response evoked by mind-body interventions, such as breathing exercises and meditation, is known to reduce stress and improve quality of life (QOL). In a recent study, mindfulness-based meditation was found to reduce intraocular pressure and improve QOL in patients with glaucoma.3 A feasibility study will be conducted using a mixed-method design to assess the feasibility of the online delivery of an intervention titled Breathing Exercises followed by Meditation for potentially enhancing the QOL and mental health of glaucoma patients. Upon recruitment, participants will undergo blocked randomization to either the intervention arm or usual care arm, stratified by sex. Participants in each arm will complete online questionnaires at baseline and after 12 weeks to collect data on health-related quality of life (HRQOL), depression symptoms, anxiety, and sleep quality using REDCap, an electronic data capturing system provided by Lawson Health Research Institute (LHRI). Our study can help to assess the feasibility of conducting a pilot study on breathing exercises followed by meditation to assess its effects in a sample of patients with glaucoma.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Breathing Exercises followed by Meditation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
Impact of Breathing Exercises and Meditation on Improving Quality of Life in Glaucoma Patients: An Electronic Pilot Feasibility Study
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Breathing Exercises followed by Meditation

Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Participants will receive three weekly online instructions (90 minutes each) by trained instructors in addition to standard care. Weekly 60 minutes follow-ups will include 10 minutes of breathing exercises followed by 33 minutes of guided meditation practice, and then focus on participants' experiences with breathing exercise followed by meditation during the week, additional observations, and a review of relevant knowledge to support their home practice.

Behavioral: Breathing Exercises followed by Meditation
Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.

No Intervention: No Intervention

The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.

Outcome Measures

Primary Outcome Measures

  1. Change in health-related quality of life (HRQoL) [Baseline visit, Week 1, Week 3, Week 6, Week 12]

    HRQoL is an essential measure of quality of life related to health; it helps physician identify hidden morbidity in clinical care as well as improves patient-physician communications. HRQoL will be measured using time trade-off questionnaire

  2. Change in Depression [Baseline visit, Week 1, Week 3, Week 6, Week 12]

    Depression is a feeling of severe despondency and dejection. Depression will be measured using the Center for Epidemiological Studies - Depression (CES-D) score.

  3. Change in Anxiety [Baseline visit, Week 1, Week 3, Week 6, Week 12]

    Anxiety will be measured using Hospital Anxiety and Depression Scale - Anxiety (HADS-A) subscale

  4. Change in Sleep quality [Baseline visit, Week 1, Week 3, Week 6, Week 12]

    Sleep quality as measured using the Pittsburgh Sleep Quality Index (PSQI) scores.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion and Exclusion Criteria Inclusion Criteria

  1. Patients diagnosed with glaucoma.

  2. Patients aged 40-65.

  3. Being able to provide valid informed consent to participate in the research study.

  4. Being able to read and understand English.

  5. Having no significant self-reported or physician-diagnosed mental health disorder.

  6. Independent access to a computer to participate in virtual sessions.

  7. Must be able to sit comfortably for 30-35 minutes without any major pain or discomfort, can hear well enough to follow verbal instructions when the eyes are closed, and be in good general physical health.

Exclusion Criteria

  1. Inability to provide valid informed consent.

  2. Significant communication barriers or lack of English proficiency that prevents participants from completing the questionnaires.

  3. Severe depression as confirmed by a CES-D ≥ 24.

  4. Having a lifetime diagnosis of self-reported other serious mental disorders, including bipolar I or II disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder).

  5. Self-reported substance abuse or dependence within the past 3 months.

  6. Having acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months.

  7. Having irreversible vision loss that prevents one from completing the questionnaires.

  8. Participation in a study involving similar techniques.

Contacts and Locations

Locations

Site City State Country Postal Code
1 St. Joseph's Hospital, Ivey Eye Institute London Ontario Canada N6G0H8

Sponsors and Collaborators

  • Lawson Health Research Institute

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Monali Malvankar, Assistant Professor, Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT05960513
Other Study ID Numbers:
  • 122096
First Posted:
Jul 25, 2023
Last Update Posted:
Jul 25, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Monali Malvankar, Assistant Professor, Lawson Health Research Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 25, 2023